Skip to main content

Summary

for people ages 50 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.

Keywords

Inflammation Fibrosis Losartan

Eligibility

You can join if…

Open to people ages 50 years and up

  • HIV infection (verified by previous positive antibody or detectable HIV RNA level)
  • Age > 50 years
  • Receiving continuous ART for >= 2 years (regimen changes > 6 months prior to enrollment are allowed)
  • HIV RNA level < 200 copies/mL for >= 1 year (1 measure >= 200 allowed if also < 1000 and preceded and followed by values < 200 copies/mL)
  • Blood CD4+ T-cell count < 600 cells/mm cubed
  • Systolic blood pressure > 120 mmHg (mean value if >= 2 measures obtained)
  • Estimated glomerular filtration rate (GFR )> 30 mL/min/1.73 m squared
  • Do not anticipate starting or stopping statin or aspirin therapy during the study

You CAN'T join if...

  • Pregnancy or breastfeeding
  • A contra-indication to taking an angiotensin receptor blocker (ARB) (e.g., cirrhosis,prior angioedema with angiotensin-converting enzyme inhibitor (ACE-I), or use of drug with potential drug-interaction [e.g., rifaximin])
  • A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD),stroke, or diabetes mellitus (DM))
  • Current treatment with ARB or medication with overlapping mechanism (e.g., ACE-I or aldosterone antagonist)
  • Current treatment with immunomodulatory drugs within the past 6 months
  • Current hepatitis treatments (e.g., interferon, ribavirin) within the past 6 months
  • Serum potassium > 5.0 millimoles per liter (mmol/L) within 3 months of entry
  • Invasive cancer in the prior year or receiving cancer treatment (not including carcinoma-in-situ or basal cell cancer of the skin)
  • Cirrhosis or end-stage liver disease
  • Rheumatologic or chronic inflammatory disease (e.g., systematic lupus erythematous,psoriasis, rheumatoid arthritis, vasculitis, sarcoidosis, Crohn's disease)

Locations

  • Allina Health accepting new patients
    Minneapolis, Minnesota, 55407, United States
  • Hennepin County Medical Center accepting new patients
    Minneapolis, Minnesota, 55417, United States
  • NIH Clinical Center accepting new patients
    Bethesda, Maryland, 20892, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Minneapolis Medical Research Foundation
ID
NCT02049307
Phase
Phase 2
Lead Scientist
Steven Deeks
Study Type
Interventional
Last Updated
September 2016
I’m interested in this study!